Co-reporter:Babatope Akinbobuyi, Lei Wang, Katherine C. Upchurch, Matthew R. Byrd, Charles A. Chang, Jeremy M. Quintana, Rachel E. Petersen, Zacharie J. Seifert, José R. Boquin, SangKon Oh, Robert R. Kane
Bioorganic & Medicinal Chemistry Letters 2016 26(16) pp: 4246-4249
Publication Date(Web):1 September 2016
DOI:10.1016/j.bmcl.2016.07.049
Fifteen new substituted adenines were synthesized as potential TLR7 agonists. These compounds, along with 9 previously reported compounds, were analyzed for TLR7 activity and for the selective stimulation of B cell proliferation. Several functionalized derivatives exhibit significant activity, suggesting their potential for use as vaccine adjuvants.
Co-reporter:Jeffrey A. SoRelle;Mazhar A. Kanak;Takeshi Itoh;Joshua M. Horton;Bashoo Naziruddin;Robert R. Kane
Journal of Biomedical Materials Research Part A 2015 Volume 103( Issue 3) pp:869-877
Publication Date(Web):
DOI:10.1002/jbm.a.35229
Abstract
Beta cell replacement therapy, the transplantation of isolated pancreatic islets by intraportal infusion, offers patients with brittle type 1 diabetes blood glucose regulation with a minimally invasive technique. Chemical modification of islets prior to transplantation, providing a nanothin barrier that potentially includes active protective compounds, has been proposed as a strategy to minimize the inflammatory and immune reactions that often significantly limit graft function and duration. Chemical modification also has the potential to allow the use of alternative sources of islets, such as porcine islets, for transplantation. This investigation compared three orthogonal covalent islet modification techniques across three species (human, porcine, and murine), using multiple measures to determine biocompatibility and effectiveness. All three conjugation chemistries were well tolerated, and the overall efficiency, gross uniformity, and stability of the surface modifications were dependent upon the conjugation chemistry as well as the islet source (human, porcine, or murine). Notably, the reductive modification of surface disulfides was shown to afford intense and long-lasting modification of human islets. This study demonstrates that murine, human, and porcine islets tolerate a variety of covalent modifications, that these modifications are relatively stable, and that the murine islet model may not be predictive for some chemical contexts. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 103A: 869–877, 2015.
Co-reporter:Babatope Akinbobuyi, Matthew R. Byrd, Charles A. Chang, Mysa Nguyen, Zacharie J. Seifert, Anne-Laure Flamar, Gerard Zurawski, Katherine C. Upchurch, SangKon Oh, Stephen H. Dempsey, Thomas J. Enke, John Le, Hunter J. Winstead, José R. Boquín, Robert R. Kane
Tetrahedron Letters 2015 Volume 56(Issue 2) pp:458-460
Publication Date(Web):8 January 2015
DOI:10.1016/j.tetlet.2014.11.126
Protein conjugates of toll-like receptor 7 agonists have been shown to elicit powerful immune responses. In order to facilitate our studies in this area our group has developed efficient syntheses for a number of functionalized derivatives that retain immune stimulatory activity.9 new TLR-7 agonists; 10–70% overall for 4–7 steps. X=H, I, CO2H, CN, CONH2, CCCH2OH, CCCH2NH2, (CH2)3NH2, CONHCH2CH2NH2, CONH-PEG2-NH2.
Co-reporter:Mallinath B. Hadimani, Jianyi Hua, M.Devan Jonklaas, Raymond J. Kessler, Yezhou Sheng, Adrian Olivares, Rajendra P. Tanpure, Aimee Weiser, Jianxing Zhang, Klaus Edvardsen, Robert R. Kane, Kevin G. Pinney
Bioorganic & Medicinal Chemistry Letters 2003 Volume 13(Issue 9) pp:1505-1508
Publication Date(Web):5 May 2003
DOI:10.1016/S0960-894X(03)00206-3
Combretastatin A-4 disodiumphosphate (CA4P), a prodrug formulation of the natural product combretastatin A-4 (CA4), is currently in clinical investigation for the treatment of cancer. In vivo, CA4P is rapidly enzymatically converted to CA4, a potent inhibitor of tubulin polymerization (IC50=1–2 μM), and rapidly causes bloodflow shutdown in tumor tissues. A variety of alkyl and aryl di- and triesters of CA4P have been synthesized and evaluated as potential CA4 prodrugs and/or stable CA4P analogues.Combretastatin A-4 disodiumphosphate (CA4P), a prodrug formulation of the natural product combretastatin A-4 (CA4), is currently in clinical investigation for the treatment of cancer. In vivo, CA4P is rapidly enzymatically converted to CA4, a potent inhibitor of tubulin polymerization (IC50=1–2 μM), and rapidly causes bloodflow shutdown in tumor tissues. A variety of alkyl and aryl di- and triesters of CA4P have been synthesized and evaluated as potential CA4 prodrugs and/or stable CA4P analogues.
Co-reporter:Keith Hyl;Aruna Perera;Robert R. Kane;Hoa K. Nguyen
Journal of Labelled Compounds and Radiopharmaceuticals 2003 Volume 46(Issue 5) pp:389-394
Publication Date(Web):17 MAR 2003
DOI:10.1002/jlcr.677
Concise methods for the synthesis of 4-hydroxy-3-[2H3]-methoxyphenylalanine (3-O-[2H3]-methydopa) and 3-hydroxy-4-[2H3]-methoxyphenylalanine (4-O-[2H3]-methydopa) are described. The 3-O-[2H3]-methydopa is a valuable internal standard for the tandem MS quantification of 3-O-methyldopa, a metabolite of value in the diagnosis of aromatic l-amino acid decarboxylase (AADC) deficiency. Copyright © 2003 John Wiley & Sons, Ltd.
Co-reporter:Jianxing Zhang, R.Jeremy Woods, Philip B Brown, Kap Duk Lee, Robert R Kane
Bioorganic & Medicinal Chemistry Letters 2002 Volume 12(Issue 6) pp:853-856
Publication Date(Web):25 March 2002
DOI:10.1016/S0960-894X(02)00050-1
A mixture of 4-alkylamino-1,8-naphthalimides has previously been reported to exhibit potential utility as a photochemical tissue-bonding reagent. In order to determine which constituents of the mixture were responsible for the observed tissue bonding and to facilitate study of the mechanism, we have synthesized each of the primary constituents of the mixture. Each naphthalimide synthesized has been demonstrated to photochemically crosslink proteins.Four hydrophilic naphthalimides were synthesized and their ability to photochemically crosslink RNase A evaluated.